Meny

Javascript is not activated in your browser. This website needs javascript activated to work properly.
Du är här

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Författare:
  • Mark Levis
  • Farhad Ravandi
  • Eunice S. Wang
  • Maria R. Baer
  • Alexander Perl
  • Steven Coutre
  • Harry Erba
  • Robert K. Stuart
  • Michele Baccarani
  • Larry D. Cripe
  • Martin S. Tallman
  • Giovanna Meloni
  • Lucy A. Godley
  • Amelia A. Langston
  • Sergio Amadori
  • Ian D. Lewis
  • Arnon Nagler
  • Richard Stone
  • Karen Yee
  • Anjali Advani
  • Dan Douer
  • W. Wiktor-Jedrzejczak
  • Gunnar Juliusson
  • Mark R. Litzow
  • Stephen Petersdorf
  • Miguel Sanz
  • Hagop M. Kantarjian
  • Takashi Sato
  • Lothar Tremmel
  • Debra M. Bensen-Kennedy
  • Donald Small
  • B. Douglas Smith
Publiceringsår: 2011
Språk: Engelska
Sidor: 3294-3301
Publikation/Tidskrift/Serie: Blood
Volym: 117
Nummer: 12
Dokumenttyp: Artikel
Förlag: American Society of Hematology

Sammanfattning

In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability. Correlative studies included pharmacokinetics and analysis of in vivo FLT3 inhibition. There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms. There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20 mu M. In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib. Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited. Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse. This study is registered at www.clinicaltrials.gov as #NCT00079482. (Blood. 2011;117(12): 3294-3301)

Disputation

Nyckelord

  • Medicine and Health Sciences

Övriga

Published
Yes
  • ISSN: 0006-4971

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen